Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week High on Analyst Upgrade

Entrada Therapeutics, Inc. (NASDAQ: TRDA - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday after Oppenheimer raised their price target on the stock from $21.00 to $23.00. Oppenheimer currently has an outperform rating on the stock. Entrada Therapeutics traded as high as $14.00 and last traded at $13.88, with a volume